GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » Total Operating Expense

Molecular Partners AG (XSWX:MOLN) Total Operating Expense : CHF69.07 Mil (TTM As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Molecular Partners AG Total Operating Expense?

Molecular Partners AG's Total Operating Expense for the three months ended in Sep. 2024 was CHF15.27 Mil. Molecular Partners AG's Total Operating Expense for the trailing twelve months (TTM) ended in Sep. 2024 was CHF69.07 Mil.

Molecular Partners AG Total Operating Expense Historical Data

The historical data trend for Molecular Partners AG's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Partners AG Total Operating Expense Chart

Molecular Partners AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 57.04 67.67 72.75 72.94 68.15

Molecular Partners AG Quarterly Data
Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.03 17.68 18.60 17.53 15.27

Molecular Partners AG Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF69.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Molecular Partners AG Total Operating Expense Related Terms

Thank you for viewing the detailed overview of Molecular Partners AG's Total Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Molecular Partners AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » Total Operating Expense
Comparable Companies
XSWX:NWRN XSWX:SANN XSWX:RLF XSWX:EVE XSWX:SPEX XSWX:OBSN XSWX:ADXN XSWX:KNRS XSWX:XLS XSWX:IDIA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
MOLN:USA MLLCF:USA MOLNz:UK 0QXX:UK
Address
Wagistrasse 14, Schlieren, Zurich, CHE, 8952
Website
https://www.molecularpartners.com
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.